Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19

Review (71 studies; n=22 058) concluded tocilizumab was associated with a lower relative risk of mortality vs controls (RR 0.83, 95% CI 0.72 to 0.96, I2=0.0%), but effects for other outcomes were inconclusive, as was evidence for efficacy of anakinra, siltuximab or sarilumab.

Thorax